Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to impose a serious burden on health systems globally. Despite worldwide vaccination, social distancing and wearing masks, the spread of the virus is ongoing. One of the mechanisms by which neutralizing antibodies (NAbs) block virus entry into cells encompasses interaction inhibition between the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and the spike (S) protein of SARS-CoV-2. SARS-CoV-2-specific NAb development can be induced in the blood of cattle. Pregnant cows produce NAbs upon immunization, and antibodies move into the colostrum immediately before calving. Here, we immunized cows with SARS-CoV-2 S1 receptor binding domain (RBD) protein in proper adjuvant solutions, followed by one boost with SARS-CoV-2 trimeric S protein and purified immunoglobulins from colostrum. We demonstrate that this preparation indeed blocks the interaction between the trimeric S protein and ACE2 in different in vitro assays. Moreover, we describe the formulation of purified immunoglobulin preparation into a nasal spray. When administered to human subjects, the formulation persisted on the nasal mucosa for at least 4 hours, as determined by a clinical study. Therefore, we are presenting a solution that shows great potential to serve as a prophylactic agent against SARS-CoV-2 infection as an additional measure to vaccination and wearing masks. Moreover, our technology allows for rapid and versatile adaptation for preparing prophylactic treatments against other diseases using the defined characteristics of antibody movement into the colostrum.

Media Type:

Electronic Article

Year of Publication:

2022

Publication:

2022

Contained In:

To Main Record - volume:17

Contained In:

PloS one - 17(2022), 6 vom: 01., Seite e0268806

Language:

English

Contributors:

Kangro, Kadri [Author]
Kurašin, Mihhail [Author]
Gildemann, Kiira [Author]
Sankovski, Eve [Author]
Žusinaite, Eva [Author]
Lello, Laura Sandra [Author]
Pert, Raini [Author]
Kavak, Ants [Author]
Poikalainen, Väino [Author]
Lepasalu, Lembit [Author]
Kuusk, Marilin [Author]
Pau, Robin [Author]
Piiskop, Sander [Author]
Rom, Siimu [Author]
Oltjer, Ruth [Author]
Tiirik, Kairi [Author]
Kogermann, Karin [Author]
Plaas, Mario [Author]
Tiirats, Toomas [Author]
Aasmäe, Birgit [Author]
Plaas, Mihkel [Author]
Mumm, Karl [Author]
Krinka, Dagni [Author]
Talpsep, Ene [Author]
Kadaja, Meelis [Author]
Gerhold, Joachim M [Author]
Planken, Anu [Author]
Tover, Andres [Author]
Merits, Andres [Author]
Männik, Andres [Author]
Ustav, Mart [Author]
Ustav, Mart [Author]

Links:

Volltext

Keywords:

Angiotensin-Converting Enzyme 2
Antibodies, Neutralizing
Antibodies, Viral
EC 3.4.17.23
Journal Article
Research Support, Non-U.S. Gov't
Spike Glycoprotein, Coronavirus
Spike protein, SARS-CoV-2

Notes:

Date Completed 14.06.2022

Date Revised 16.07.2022

published: Electronic-eCollection

Citation Status MEDLINE

doi:

10.1371/journal.pone.0268806

funding:

Supporting institution / Project title:

PPN (Catalogue-ID):

NLM342092359